David Cade, Sumanta Kumar Pal, Andrew Mark Scott, Thea Faivre. "Phase 3 study to assess the safety and efficacy of
                    <sup>177</sup>
                    Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.tps4631